Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-MAPT-SC in Healthy Subjects and Early Alzheimer's Disease
NCT07221344Phase 2Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of ARO-MAPT-SC in Alzheimer's disease (AD), sponsored by Arrowhead Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
ARO-MAPT-SC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07221344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221344.